Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03017573 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Study acronym: SCANDARE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 6 wordsv11
  2. Study sites: 5 to 6v10
  3. Enrollment target: 700 to 1050v9 Show 4 more changesShow less
    • Primary completion date: Aug 2028 to Aug 6, 2029
    • Study completion date: Jan 6, 2031 to Jan 6, 2032
    • Eligibility criteria expanded, about 19 words
    • Study title shortened, about 7 words
  4. Site details revised at 2 of 5 sitesv8
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Aug 2026 to Aug 2028v6 Show 5 more changesShow less
    • Study sites: 2 to 5
    • Study completion date: Jan 2029 to Jan 6, 2031
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: 4 to 5
    • Study title expanded, about 1 word
  2. Primary completion date: Aug 2024 to Aug 2026
    • Enrollment target: 600 to 700
    • Study completion date: Feb 2026 to Jan 2029
    • Study description expanded, about 16 words
    v5
  3. Primary completion date: Dec 2020 to Aug 2024v4 Show 4 more changesShow less
    • Enrollment target: 500 to 600
    • Study completion date: Dec 2023 to Feb 2026
    • Start date: Dec 2016 to Jan 6, 2017
    • Study description expanded, about 12 words
  4. Site contacts updated at 1 of 2 sitesv3
  5. Site details revised at 1 of 2 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
Ovarian Cancer
1,336 trials monitored
See 90 trials at risk
and 3 more diseases
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.
Trial Details
NCT Number NCT03017573
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer, Sarcoma, Vulva Cancer
Related terms Head and Neck Neoplasms, Ovarian Neoplasms, Sarcoma, Triple Negative Breast Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms
Enrollment 1,050 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov